Free Trial
→ Watch This Now (From StocksToTrade) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Basilea Pharmaceutica AG stock logo
BPMUF
Basilea Pharmaceutica
$84.00
+8.5%		$76.89
$59.29
▼
$84.00
$1.00B0.22N/A10 shs
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
$11.47
+0.9%		$11.33
$6.39
▼
$26.95
$959.09M1.571.02 million shs822,120 shs
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
$1.11
+6.7%		$1.00
$0.88
▼
$1.99
$263.02M1.681.33 million shs1.70 million shs
ODTX
Odyssey Therapeutics
$20.99
+5.0%		$20.91
$15.10
▼
$29.05
$961.36MN/A309,672 shs245,072 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Basilea Pharmaceutica AG stock logo
BPMUF
Basilea Pharmaceutica
+10.16%+10.16%+10.16%+28.24%+41.68%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
+0.88%+8.51%+14.13%-24.24%+40.39%
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
+6.73%+7.77%+16.34%+4.72%-39.01%
ODTX
Odyssey Therapeutics
+4.95%+7.64%+14.95%+1.30%+2,098,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Basilea Pharmaceutica AG stock logo
BPMUF
Basilea Pharmaceutica
$84.00
+8.5%		$76.89
$59.29
▼
$84.00
$1.00B0.22N/A10 shs
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
$11.47
+0.9%		$11.33
$6.39
▼
$26.95
$959.09M1.571.02 million shs822,120 shs
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
$1.11
+6.7%		$1.00
$0.88
▼
$1.99
$263.02M1.681.33 million shs1.70 million shs
ODTX
Odyssey Therapeutics
$20.99
+5.0%		$20.91
$15.10
▼
$29.05
$961.36MN/A309,672 shs245,072 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Basilea Pharmaceutica AG stock logo
BPMUF
Basilea Pharmaceutica
+10.16%+10.16%+10.16%+28.24%+41.68%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
+0.88%+8.51%+14.13%-24.24%+40.39%
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
+6.73%+7.77%+16.34%+4.72%-39.01%
ODTX
Odyssey Therapeutics
+4.95%+7.64%+14.95%+1.30%+2,098,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Basilea Pharmaceutica AG stock logo
BPMUF
Basilea Pharmaceutica
0.00
N/AN/AN/A
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
2.88
Moderate Buy$32.83186.25% Upside
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
3.00
Buy$6.25463.06% Upside
ODTX
Odyssey Therapeutics
2.80
Moderate Buy$34.6765.16% Upside

Current Analyst Ratings Breakdown

Latest LCTX, BPMUF, ODTX, and CRVS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/6/2026
ODTX
Odyssey Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$40.00
10/29/2026
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$27.00
10/26/2026
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/12/2026
ODTX
Odyssey Therapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$27.00
10/12/2026
ODTX
Odyssey Therapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong-Buy
10/8/2026
ODTX
Odyssey Therapeutics
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOutperform$42.00
10/8/2026
ODTX
Odyssey Therapeutics
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOutperform$42.00
9/16/2026
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight
8/27/2026
ODTX
Odyssey Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$44.00
8/27/2026
ODTX
Odyssey Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$44.00
(Data available from 11/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Basilea Pharmaceutica AG stock logo
BPMUF
Basilea Pharmaceutica
$280.43M3.94$4.24 per share19.81$11.73 per share7.16
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/A$0.13 per share89.70$2.47 per shareN/A
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
$14.56M19.28N/AN/A$0.19 per share5.84
ODTX
Odyssey Therapeutics
N/AN/AN/AN/A$7.82 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Basilea Pharmaceutica AG stock logo
BPMUF
Basilea Pharmaceutica
$48.57MN/AN/AN/AN/AN/AN/AN/AN/A
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$15.28M-$0.71N/AN/AN/AN/A-34.98%-32.67%N/A
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
-$63.53M-$0.12N/AN/AN/A-246.58%-73.06%-30.87%11/12/2026 (Estimated)
ODTX
Odyssey Therapeutics
N/A-$9.13N/AN/AN/AN/AN/AN/AN/A

Latest LCTX, BPMUF, ODTX, and CRVS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
-$0.0286N/AN/AN/A$2.32 millionN/A
11/5/2026Q3 2026
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$0.1924-$0.22-$0.0276-$0.22N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Basilea Pharmaceutica AG stock logo
BPMUF
Basilea Pharmaceutica
N/AN/AN/AN/AN/A
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/AN/AN/AN/A
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
N/AN/AN/AN/AN/A
ODTX
Odyssey Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Basilea Pharmaceutica AG stock logo
BPMUF
Basilea Pharmaceutica
0.44
6.60
5.97
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/A
13.38
13.38
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
N/A
6.61
6.61
ODTX
Odyssey Therapeutics
N/A
12.94
12.94

Institutional Ownership

CompanyInstitutional Ownership
Basilea Pharmaceutica AG stock logo
BPMUF
Basilea Pharmaceutica
N/A
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
46.64%
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
62.47%
ODTX
Odyssey Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Basilea Pharmaceutica AG stock logo
BPMUF
Basilea Pharmaceutica
N/A
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
19.70%
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
24.70%
ODTX
Odyssey Therapeutics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Basilea Pharmaceutica AG stock logo
BPMUF
Basilea Pharmaceutica
18913.17 millionN/ANot Optionable
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
3784.35 million67.74 millionOptionable
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
77252.91 million190.44 millionNot Optionable
ODTX
Odyssey Therapeutics
10048.07 millionN/AN/A

Recent News About These Companies

What is HC Wainwright's Estimate for ODTX FY2026 Earnings?
November 12 at 1:43 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31192971
Why Odyssey Therapeutics, Inc.’s (ODTX) Stock Is Up 5.01%
November 10 at 11:52 PM  |  aaii.comA
Odyssey Therapeutics Announces Publication Highlighting Differentiated Therapeutic Potential of TNFR2 Agonism
November 10 at 8:49 AM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/odyssey-therapeutics-announces-publication-highlighting-differentiated-therapeutic-potential-of-tnfr2-agonism-1036742405
What is HC Wainwright's Forecast for ODTX FY2026 Earnings?
November 10 at 6:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-what-is-hc-wainwrights-forecast-for-odtx-fy2026-earnings-2026-11-10/
What is HC Wainwright's Forecast for ODTX Q1 Earnings?
November 9 at 1:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31186867
What is HC Wainwright's Estimate for ODTX Q1 Earnings?
November 9 at 1:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-what-is-hc-wainwrights-estimate-for-odtx-q1-earnings-2026-11-09/
Odyssey Therapeutics Advances Early OD-001 Study as Investors Watch for Drug Development Signals
November 5, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/odyssey-therapeutics-advances-early-od-001-study-as-investors-watch-for-drug-development-signals?utm_source=marketbeat.com&utm_medium=referral
Odyssey Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026
November 4, 2026  |  marketscreener.comM
Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
November 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/odyssey-therapeutics-reports-third-quarter-120000973.html
Odyssey Therapeutics: Q3 earnings snapshot
November 4, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/odyssey-therapeutics-q3-earnings-snapshot/ar-AA2gK4pc
Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Stock Has Consensus Price Target of $35.33
October 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-odyssey-therapeutics-inc-nasdaq-odtx-stock-has-consensus-price-target-of-3533-2026-10-30/
Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts
October 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-odyssey-therapeutics-highlights-od-001-phase-iia-uc-data-sets-2027-trial-readouts-2026-10-25/
Odyssey Therapeutics, Inc. Presents Completed Phase 2A Od-001 Induction Results Strengthening Clinical Proof of Concept At Ueg Week 2026
October 21, 2026  |  marketscreener.comM
Odyssey Therapeutics, Inc. (ODTX) Discusses Additional Phase IIa Data for OD-001 in Ulcerative Colitis from UEG Week Presentation Transcript
October 20, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4955641-odyssey-therapeutics-inc-odtx-discusses-additional-phase-iia-data-for-odminus-001-in
Odyseey's OD-001 Shows Clinical Activity In Ulcerative Colitis, Advanced To Next Trial Stage
October 20, 2026  |  rttnews.comhttps://www.rttnews.com/3700616/odyseey-s-od-001-shows-clinical-activity-in-ulcerative-colitis-advanced-to-next-trial-stage.aspx
Odyssey Therapeutics Announces Encouraging Phase 2a Ulcerative Colitis Results
October 20, 2026  |  rttnews.comhttps://www.rttnews.com/3700579/odyssey-therapeutics-announces-encouraging-phase-2a-ulcerative-colitis-results.aspx
Odyssey Therapeutics Reports Positive Phase 2a Ulcerative Colitis Data for Oral OD-001, Supporting Further Development
October 20, 2026  |  quiverquant.comQ
Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026
October 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/20/3384218/0/en/odyssey-therapeutics-presents-completed-phase-2a-od-001-induction-results-strengthening-clinical-proof-of-concept-at-ueg-week-2026.html
Odyssey Therapeutics (NASDAQ:ODTX) Upgraded at UBS Group
October 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-odyssey-therapeutics-nasdaq-odtx-upgraded-at-ubs-group-2026-10-14/
Odyssey Therapeutics Presents Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026
October 13, 2026  |  marketscreener.comM
Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026
October 12, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/odyssey-therapeutics-to-present-design-of-phase-2a-study-evaluating-od-001-in-combination-with-vedolizumab-at-acg-2026-1036616307

New MarketBeat Followers Over Time

Media Sentiment Over Time

Basilea Pharmaceutica stock logo

Basilea Pharmaceutica OTCMKTS:BPMUF

$84.00 +6.60 (+8.53%)
As of 11/11/2026 01:15 PM Eastern

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.

Corvus Pharmaceuticals stock logo

Corvus Pharmaceuticals NASDAQ:CRVS

$11.47 +0.10 (+0.88%)
Closing price 11/11/2026 04:00 PM Eastern
Extended Trading
$11.24 -0.23 (-1.96%)
As of 08:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Lineage Cell Therapeutics stock logo

Lineage Cell Therapeutics NYSEAMERICAN:LCTX

$1.11 +0.07 (+6.73%)
Closing price 11/11/2026 04:10 PM Eastern
Extended Trading
$1.09 -0.02 (-1.80%)
As of 08:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Odyssey Therapeutics NASDAQ:ODTX

$20.99 +0.99 (+4.95%)
As of 11/11/2026 04:00 PM Eastern

Odyssey Therapeutics Inc. is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc. is based in BOSTON.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas